Suppr超能文献

给予小分子免疫调节拮抗剂的食蟹猴细菌感染。

Bacterial infections in cynomolgus monkeys given small molecule immunomodulatory antagonists.

机构信息

Bristol-Myers Squibb Company, East Syracuse, NY 13057-5050, USA.

出版信息

J Immunotoxicol. 2010 Apr-Jun;7(2):128-37. doi: 10.3109/15476910903493276.

Abstract

Opportunistic infections (OIs) during the course of non-clinical toxicity studies can serve as a clinical indicator of immunosuppression. In monkeys, severity may be magnified since the possibility for fecal-oral and cage-to-cage transmission of bacteria exists, reserve capacity is low, and clinical signs of infection are not easily detected until the infectious process is well underway. This review summarizes a case study presented at the HESI-ILSI ITC-Sponsored workshop on Naturally Occurring Infections in Non-human Primates and Immunotoxicity Implications. It gives an overview on the impact of bacterial infections in monkeys on the development and regulatory assessment of three closely-related representative small molecule immunomodulatory (anti-inflammatory) drug candidates all inhibiting the same drug target. The infections, which sometimes progressed to bacteremia and death, originally manifested in the skin, upper respiratory tract, gastrointestinal tract, and less frequently as soft tissue abscesses. Infections were sporadic and not observed in all studies despite coverage of equivalent or higher systemic exposures or longer durations of treatment. To address concerns regarding inconsistency in the presentation and type of findings and their potential relationship to infection, steps were taken to identify causative agents (via culture, microscopy), implement various intervention and treatment regimens (supportive care, antibiotics, drug holiday), demonstrate reversibility of clinical and immune effects, and study major immune components/mechanisms affected (cytokine/stress protein profiling, immune cell phenotyping, and humoral/innate immune cell function tests). Appropriate diagnosis and characterization of the infection was critical to discrimination of these findings as a secondary pharmacologic effect rather than a direct drug-related target organ effect, and also guided clinical protocol design and regulatory acceptance.

摘要

在非临床毒性研究过程中,机会性感染(OIs)可以作为免疫抑制的临床指标。在猴子中,由于存在粪便-口腔和笼对笼传播细菌的可能性、储备能力低以及感染过程进展到一定阶段之前不易检测到感染的临床症状,严重程度可能会加剧。本综述总结了在 HESI-ILSI ITC 赞助的非人类灵长类动物自然发生感染和免疫毒性影响研讨会上提出的一项案例研究。它概述了细菌感染对猴子的影响,这些感染对三种密切相关的代表性小分子免疫调节(抗炎)药物候选物的开发和监管评估产生了影响,这些候选物均抑制相同的药物靶点。这些感染有时会进展为菌血症和死亡,最初表现为皮肤、上呼吸道、胃肠道感染,较少表现为软组织脓肿。尽管系统暴露等效或更高,或治疗时间更长,但并非所有研究都观察到感染,感染是零星发生的。为了解决在呈现和发现类型方面的不一致性以及它们与感染的潜在关系问题,采取了措施来确定病原体(通过培养、显微镜),实施各种干预和治疗方案(支持性护理、抗生素、药物休假),证明临床和免疫效应的可逆性,并研究受影响的主要免疫成分/机制(细胞因子/应激蛋白谱分析、免疫细胞表型分析以及体液/先天免疫细胞功能测试)。感染的适当诊断和特征对于将这些发现区分作为次要的药物药理作用,而不是直接的药物相关靶器官作用至关重要,并且还指导了临床方案设计和监管接受。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验